Helicobacter pylori infection: from standard to alternative treatment strategies

References

• Abadi AH, Mahdavi M, Khaledi A, Esmaeili SA, Esmaeili D, Sahebkar A. 2018. Study of serum bactericidal and splenic activity of total-OMP- CagA combination from Brucella abortus and Helicobacter pylori in BALB/c mouse model. Microb Pathog. 121:100–105.
   PubMed Web of Science ®Google Scholar
• Abadi ATB. 2016. Vaccine against Helicobacter pylori: inevitable approach. World J Gastroenterol. 22(11):3150–3157.
   PubMed Web of Science ®Google Scholar
• Abdel-Haliem ME, Askora A. 2013. Isolation and characterization of bacteriophages of Helicobacter pylori isolted from Egypt. Future Virol. 8(8):821–826.
   Web of Science ®Google Scholar
• Alves de Matos AP, Lehours P, Timóteo A, Roxo-Rosa M, Vale FF. 2013. Comparison of induction of B45 Helicobacter pylori prophage by acid and UV radiation. Microsc Microanal. 19(S4):27–28.
   Google Scholar
• Arif M, Dong QJ, Raja MA, Zeenat S, Chi Z, Liu CG. 2018. Development of novel pH-sensitive thiolated chitosan/PMLA nanoparticles for amoxicillin delivery to treat Helicobacter pylori. Mater Sci Eng C Mater Biol Appl. 83:17–24.
   PubMed Web of Science ®Google Scholar
• Arslan N, Yilmaz Ö, Demiray-Gürbüz E. 2017. Importance of antimicrobial susceptibility testing for the management of eradication in Helicobacter pylori infection. World J Gastroenterol. 23(16):2854–2869.
   PubMed Web of Science ®Google Scholar
• Attari VE, Somi MH, Jafarabadi MA, Ostadrahimi A, Moaddab SY, Lotfi N. 2019. The gastro-protective effect of ginger (Zingiber officinale roscoe) in Helicobacter pylori positive functional dyspepsia. Adv Pharm Bull. 9(2):321–324.
   PubMed Web of Science ®Google Scholar
• Azadi M, Ebrahimi A, Khaledi A, Esmaeili D. 2019. Study of inhibitory effects of the mixture of cinnamon and ginger extracts on cagA gene expression of Helicobacter pylori by Real-Time RT-PCR technique. Gene Reports. 17:100493.
   Web of Science ®Google Scholar
• Azevedo NF, Huntington J, Goodman KJ. 2009. The epidemiology of Helicobacter pylori and public health implications. Helicobacter. 14:1–7.
   PubMed Web of Science ®Google Scholar
• Baccani I, Faraoni P, Marini M, Gnerucci A, Orsini B, Pecile P, Romano G, Fusi F, Rossolini GM, Antonelli A. 2019. Synergistic effect of photodynamic therapy at 400 nm and doxycycline against Helicobacter pylori. Future Microbiol. 14:1199–1205.
   PubMed Web of Science ®Google Scholar
• Baltas N, Karaoglu SA, Tarakci C, Kolayli S. 2016. Effect of propolis in gastric disorders: inhibition studies on the growth of Helicobacter pylori and production of its urease. J Enzyme Inhib Med Chem. 31(2):46–50.
   PubMedGoogle Scholar
• Baskaran R, Lee J, Yang S-G. 2018. Clinical development of photodynamic agents and therapeutic applications. Biomater Res. 22:25.
   PubMedGoogle Scholar
• Battisti A, Morici P, Ghetti F, Sgarbossa A. 2017. Spectroscopic characterization and fluorescence imaging of Helicobacter pylori endogenous porphyrins. Biophys Chem. 229:19–24. 104
   PubMed Web of Science ®Google Scholar
• Battisti A, Morici P, Signore G, Ghetti F, Sgarbossa A. 2017. Compositional analysis of endogenous porphyrins from Helicobacter pylori. Biophys Chem. 229:25–30. 103
   PubMed Web of Science ®Google Scholar
• Bebb JR, Bailey-Flitter N, Ala’Aldeen D, Atherton JC. 2003. Mastic gum has no effect on Helicobacter pylori load in vivo. J Antimicrob Chemother. 52(3):522–523.
   PubMed Web of Science ®Google Scholar
• Bik EM, Eckburg PB, Gill SR, Nelson KE, Purdom EA, Francois F, Perez-Perez G, Blaser MJ, Relman DA. 2006. Molecular analysis of the bacterial microbiota in the human stomach. Proc Natl Acad Sci USA. 103(3):732–737.
   PubMed Web of Science ®Google Scholar
• Blaser MJ. 2002. Polymorphic bacteria persisting in polymorphic hosts: assessing Helicobacter pylori-related risks for gastric cancer. J Natl Cancer Inst. 94(22):1662–1663.
   PubMedGoogle Scholar
• Blecher K, Nasir A, Friedman A. 2011. The growing role of nanotechnology in combating infectious disease. Virulence. 2(5):395–401.
   PubMed Web of Science ®Google Scholar
• Boyanova L, Gergova G, Markovska R, Yordanov D, Mitov I. 2017. Bacteriocin-like inhibitory activities of seven Lactobacillus delbrueckii subsp. bulgaricus strains against antibiotic susceptible and resistant Helicobacter pylori strains. Lett Appl Microbiol. 65(6):469–474.
   PubMed Web of Science ®Google Scholar
• Briers Y, Walmagh M, Grymonprez B, Biebl M, Pirnay J-P, Defraine V, Michiels J, Cenens W, Aertsen A, Miller S, et al. 2014. Art-175 is a highly efficient antibacterial against multidrug-resistant strains and persisters of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 58(7):3774–3784.
   PubMed Web of Science ®Google Scholar
• Briers Y, Walmagh M, Van Puyenbroeck V, Cornelissen A, Cenens W, Aertsen A, Oliveira H, Azeredo J, Verween G, Pirnay J-P, et al. 2014. Engineered endolysin-based “Artilysins” to combat multidrug-resistant Gram-negative pathogens. MBio. 5(4):e01379.
   PubMed Web of Science ®Google Scholar
• Brogden KA. 2005. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat Rev Microbiol. 3(3):238–250.
   PubMed Web of Science ®Google Scholar
• Butorova LI, Ardatskaya MD, Osadchuk MA, Kadnikova NG, Lukianova EI, Plavnik RG, Sayutina EV, Topchiy TB, Tuayeva EM. 2020. [Comparison of clinical-metabolic efficacy of pre- and probiotics in the conducted optimized protocols of eradication therapy of Helicobacter pylori infection]. Ter Arkh. 92(4):64–69. Russian.
   PubMed Web of Science ®Google Scholar
• Casey E, van Sinderen D, Mahony J. 2018. In vitro characteristics of phages to guide ‘real life’ phage therapy suitability. Viruses. 10(4):163.
   Web of Science ®Google Scholar
• Castano AP, Demidova TN, Hamblin MR. 2005. Mechanisms in photodynamic therapy: part two-cellular signaling, cell metabolism and modes of cell death. Photodiagnosis Photodyn Ther. 2(1):1–93.
   PubMed Web of Science ®Google Scholar
• Chehelgerdi M, Doosti A. 2020. Effect of the cagW-based gene vaccine on the immunologic properties of BALB/c mouse: an efficient candidate for Helicobacter pylori DNA vaccine. J Nanobiotechnology. 18(1):63.
   PubMed Web of Science ®Google Scholar
• Chen C-C, Liou J-M, Lee Y-C, Hong T-C, El-Omar EM, Wu M-S. 2021. The interplay between Helicobacter pylori and gastrointestinal microbiota. Gut Microbes. 13(1):1–22.
   PubMed Web of Science ®Google Scholar
• Chen J, Zhong Y, Liu Y, Tang C, Zhang Y, Wei B, Chen W, Liu M. 2020. Parenteral immunization with a cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) adjuvanted Helicobacter pylori vaccine induces protective immunity against H. pylori infection in mice. Hum Vaccin Immunother. 16(11):2849–2854.
   PubMed Web of Science ®Google Scholar
• Chen L, Xu W, Lee A, He J, Huang B, Zheng W, Su T, Lai S, Long Y, Chu H, et al. 2018. The impact of Helicobacter pylori infection, eradication therapy and probiotic supplementation on gut microenvironment homeostasis: an open-label, randomized clinical trial. EBioMedicine. 35:87–96.
   PubMed Web of Science ®Google Scholar
• Chey WD, Leontiadis GI, Howden CW, Moss SF. 2017. ACG clinical guideline: treatment of Helicobacter pylori Infection. Am J Gastroenterol. 112(2):212–238.
   PubMed Web of Science ®Google Scholar
• Chua C-S, Yang K-C, Chen J-H, Liu Y-H, Hsu Y-H, Lee H-C, Huang S-Y. 2016. The efficacy of blueberry and grape seed extract combination on triple therapy for Helicobacter pylori eradication: a randomised controlled trial. Int J Food Sci Nutr. 67(2):177–183.
   PubMed Web of Science ®Google Scholar
• Cirmi S, Bisignano C, Mandalari G, Navarra M. 2016. Anti-infective potential of Citrus bergamia Risso et Poiteau (bergamot) derivatives: a systematic review. Phytother Res. 30(9):1404–1411.
   PubMed Web of Science ®Google Scholar
• Cisek AA, Dąbrowska I, Gregorczyk KP, Wyżewski Z. 2017. Phage therapy in bacterial infections treatment: one hundred years after the discovery of bacteriophages. Curr Microbiol. 74(2):277–283.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. 2020. Phase 1a/b study on safety of IMX101 in H. Pylori-negative and H. Pylori-infected healthy volunteers - full text view. Bethesda (MD): NIH; [Accessed 2020 May 26]. https://clinicaltrials.gov/ct2/show/NCT03270800
   Google Scholar
• Cover TL, Blaser MJ. 2009. Helicobacter pylori in health and disease. Gastroenterology. 136(6):1863–1873.
   PubMed Web of Science ®Google Scholar
• Cuomo P, Papaianni M, Fulgione A, Guerra F, Capparelli R, Medaglia C. 2020. An innovative approach to control H. pylori-induced persistent inflammation and colonization. Microorganisms. 8:1–13.
   Web of Science ®Google Scholar
• Dabos KJ, Sfika E, Vlatta LJ, Giannikopoulos G. 2010. The effect of mastic gum on Helicobacter pylori: a randomized pilot study. Phytomedicine. 17(3–4):296–299.
   PubMed Web of Science ®Google Scholar
• Darmani H, Am Smadi E, Mb Bataineh S. 2019. Blue light emitting diodes cripple Helicobacter pylori by targeting its virulence factors. Minerva Gastroenterol Dietol. 65(3):187–192.
   PubMed Web of Science ®Google Scholar
• Darmani H, Smadi EAM, Bataineh SMB. 2020. Blue light emitting diodes enhance the antivirulence effects of Curcumin against Helicobacter pylori. J Med Microbiol. 69(4):617–624.
   PubMed Web of Science ®Google Scholar
• Davani-Davari D, Negahdaripour M, Karimzadeh I, Seifan M, Mohkam M, Masoumi SJ, Berenjian A, Ghasemi Y. 2019. Prebiotics: definition, types, sources, mechanisms, and clinical applications. Foods. 8(3):92.
   PubMed Web of Science ®Google Scholar
• Davies EV, Winstanley C, Fothergill JL, James CE. 2016. The role of temperate bacteriophages in bacterial infection. FEMS Microbiol Lett. 363(5):fnw015.
   PubMed Web of Science ®Google Scholar
• Davison AJ. 2017. Introduction to ‘ICTV virus taxonomy profiles’. J Gen Virol. 98(1):1.
   PubMed Web of Science ®Google Scholar
• de Klerk N, Maudsdotter L, Gebreegziabher H, Saroj SD, Eriksson B, Eriksson OS, Roos S, Lindén S, Sjölinder H, Jonsson A-B. 2016. Lactobacilli reduce Helicobacter pylori attachment to host gastric epithelial cells by inhibiting adhesion gene expression. Infect Immun. 84(5):1526–1535.
   PubMed Web of Science ®Google Scholar
• D’Herelle F. 2007. On an invisible microbe antagonistic toward dysenteric bacilli: brief note by Mr. F. D’Herelle, presented by Mr. Roux. 1917. Res Microbiol. 158(7):553–554.
   PubMed Web of Science ®Google Scholar
• Emara MH, Elhawari SA, Yousef S, Radwan MI, Abdel-Aziz HR. 2016. Emerging role of probiotics in the management of Helicobacter pylori infection: histopathologic perspectives. Helicobacter. 21(1):3–10.
   PubMed Web of Science ®Google Scholar
• Fallone CA, Chiba N, van Zanten SV, Fischbach L, Gisbert JP, Hunt RH, Jones NL, Render C, Leontiadis GI, Moayyedi P, et al. 2016. The Toronto Consensus for the treatment of Helicobacter pylori infection in adults. Gastroenterology. 151(1):51–69.
   PubMed Web of Science ®Google Scholar
• Fallone CA, Moss SF, Malfertheiner P. 2019. Reconciliation of recent Helicobacter pylori treatment guidelines in a time of increasing resistance to antibiotics. Gastroenterology. 157(1):44–53.
   PubMed Web of Science ®Google Scholar
• Fan X, Li Y, He R, Li Q, He W. 2016. Comparative analysis of prophage-like elements in Helicobacter sp. genomes. PeerJ. 4:e2012.
   PubMed Web of Science ®Google Scholar
• Faraoni P, Gnerucci A, Ranaldi F, Orsini B, Romano G, Fusi F. 2018. Side effects of intra-gastric photodynamic therapy: an in vitro study. J Photochem Photobiol B. 186:107–115.
   PubMed Web of Science ®Google Scholar
• Fargnoli MC, Peris K. 2015. Photodynamic therapy for basal cell carcinoma. Future Oncol. 11(22):2991–2996.
   PubMed Web of Science ®Google Scholar
• Feng J-R, Wang F, Qiu X, McFarland LV, Chen P-F, Zhou R, Liu J, Zhao Q, Li J. 2017. Efficacy and safety of probiotic-supplemented triple therapy for eradication of Helicobacter pylori in children: a systematic review and network meta-analysis. Eur J Clin Pharmacol. 73(10):1199–1208.
   PubMed Web of Science ®Google Scholar
• Ferreira RM, Machado JC, Figueiredo C. 2014. Clinical relevance of Helicobacter pylori vacA and cagA genotypes in gastric carcinoma. Best practice and research. Clin Gastroenterol. 28(6):1003–1015.
   Google Scholar
• Ferreira RM, Pereira-Marques J, Pinto-Ribeiro I, Costa JL, Carneiro F, Machado JC, Figueiredo C. 2018. Gastric microbial community profiling reveals a dysbiotic cancer-associated microbiota. Gut. 67(2):226–236.
   PubMed Web of Science ®Google Scholar
• Ford A, Delaney B, Forman D, P. Eradication Therapy For M. 2003. Peptic ulcer disease in Helicobacter pylori positive patients. In: Cochrane Database of Systematic Reviews. New York (NY): John Wiley & Sons, Ltd.
   Google Scholar
• Fortier L-C, Sekulovic O. 2013. Importance of prophages to evolution and virulence of bacterial pathogens. Virulence. 4(5):354–365.
   PubMed Web of Science ®Google Scholar
• Franceschi F, Zuccalà G, Roccarina D, Gasbarrini A. 2014. Clinical effects of Helicobacter pylori outside the stomach. Nat Rev Gastroenterol Hepatol. 11(4):234–242.
   PubMed Web of Science ®Google Scholar
• Fuochi V, Petronio GP, Lissandrello E, Furneri PM. 2015. Evaluation of resistance to low pH and bile salts of human Lactobacillus spp. isolates. Int J Immunopathol Pharmacol. 28(3):426–433.
   PubMed Web of Science ®Google Scholar
• Furuta T, Shirai N, Xiao F, El-Omar EM, Rabkin CS, Sugimura H, Ishizaki T, Ohashi K. 2004. Polymorphism of interleukin-1β affects the eradication rates of Helicobacter pylori by triple therapy. Clin Gastroenterol Hepatol. 2(1):22–30.
   PubMed Web of Science ®Google Scholar
• Gaber DA, Alhawas HS, Alfadhel FA, Abdoun SA, Alsubaiyel AM, Alsawi RM. 2020. Mini-tablets versus nanoparticles for controlling the release of amoxicillin: in vitro/in vivo study. Drug Des Devel Ther. 14:5405–5418.
   PubMed Web of Science ®Google Scholar
• Galtier M, De Sordi L, Sivignon A, de Vallée A, Maura D, Neut C, Rahmouni O, Wannerberger K, Darfeuille-Michaud A, Desreumaux P, et al. 2017. Bacteriophages targeting adherent invasive Escherichia coli strains as a promising new treatment for Crohn’s disease. J Crohns Colitis. 11(7):840–847.
   PubMed Web of Science ®Google Scholar
• Garg U, Chauhan S, Nagaich U, Jain N. 2019. Current advances in chitosan nanoparticles based drug delivery and targeting. Adv Pharm Bull. 9(2):195–204.
   PubMed Web of Science ®Google Scholar
• Gatta L, Vakil N, Vaira D, Scarpignato C. 2013. Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy. BMJ. 347:f4587.
   PubMed Web of Science ®Google Scholar
• Georgopoulos S, Papastergiou V. 2021. An update on current and advancing pharmacotherapy options for the treatment of H. pylori infection. Expert Opin Pharmacother. 22(6):729–741.
   PubMed Web of Science ®Google Scholar
• Gerhard M, Lehn N, Neumayer N, Borén T, Rad R, Schepp W, Miehlke S, Classen M, Prinz C. 1999. Clinical relevance of the Helicobacter pylori gene for blood-group antigen-binding adhesin. Proc Natl Acad Sci USA. 96(22):12778–12783.
   PubMed Web of Science ®Google Scholar
• Ghasemian A, Fattahi A, Shokouhi Mostafavi SK, Almarzoqi AH, Memariani M, Ben Braiek O, Yassine HM, Mostafavi NSS, Ahmed MM, Mirforughi SA, et al. 2019. Herbal medicine as an auspicious therapeutic approach for the eradication of Helicobacter pylori infection: a concise review. J Cell Physiol. 234(10):16847–16860.
   PubMed Web of Science ®Google Scholar
• Ghosh P, Bhakta S, Bhattacharya M, Sharma AR, Sharma G, Lee S-S, Chakraborty C. 2021. A novel multi-epitopic peptide vaccine candidate against Helicobacter pylori: in-silico identification, design, cloning and validation through molecular dynamics. Int J Pept Res Ther. 27:1–18.
   PubMed Web of Science ®Google Scholar
• Ghotaslou R, Leylabadlo HE, Asl YM. 2015. Prevalence of antibiotic resistance in Helicobacter pylori: a recent literature review. World J Methodol. 5(3):164–174.
   PubMedGoogle Scholar
• Gnerucci A, Faraoni P, Calusi S, Fusi F, Romano G. 2020. Influence of stomach mucosa tissue on the efficacy of intragastric antibacterial PDT. Photochem Photobiol Sci. 19(1):34–39.
   PubMed Web of Science ®Google Scholar
• Gopalakrishnan V, Masanam E, Ramkumar VS, Baskaraligam V, Selvaraj G. 2020. Influence of N-acylhomoserine lactonase silver nanoparticles on the quorum sensing system of Helicobacter pylori: a potential strategy to combat biofilm formation. J Basic Microbiol. 60(3):207–215.
   PubMed Web of Science ®Google Scholar
• Gopinath V, Priyadarshini S, MubarakAli D, Loke MF, Thajuddin N, Alharbi NS, Yadavalli T, Alagiri M, Vadivelu J. 2019. Anti-Helicobacter pylori, cytotoxicity and catalytic activity of biosynthesized gold nanoparticles: multifaceted application. Arab J Chem. 12(1):33–40.
   Web of Science ®Google Scholar
• Gotoda T, Takano C, Kusano C, Suzuki S, Ikehara H, Hayakawa S, Andoh A. 2018. Gut microbiome can be restored without adverse events after Helicobacter pylori eradication therapy in teenagers. Helicobacter. 23(6):e12541.
   PubMed Web of Science ®Google Scholar
• Graham DY, Shiotani A. 2008. New concepts of resistance in the treatment of Helicobacter pylori infections. Nat Clin Pract Gastroenterol Hepatol. 5(6):321–331.
   PubMedGoogle Scholar
• Graham DY. 1989. Campylobacter pylori and peptic ulcer disease. Gastroenterology. 96(2):615–625.
   PubMed Web of Science ®Google Scholar
• Guevara B, Cogdill AG. 2020. Helicobacter pylori: a review of current diagnostic and management strategies. Dig Dis Sci. 65(7):1917–1931.
   PubMed Web of Science ®Google Scholar
• Guo L, Yang H, Tang F, Yin R, Liu H, Gong X, Wei J, Zhang Y, Xu G, Liu K. 2017. Oral Immunization with a multivalent epitope-based vaccine, based on NAP, Urease, HSP60, and HpaA, provides therapeutic effect on H. pylori infection in Mongolian gerbils. Front Cell Infect Microbiol. 7:349.
   PubMed Web of Science ®Google Scholar
• Guo L, Yin R, Xu G, Gong X, Chang Z, Hong D, Liu H, Ding S, Han X, Li Y, et al. 2017. Immunologic properties and therapeutic efficacy of a multivalent epitope-based vaccine against four Helicobacter pylori adhesins (urease, Lpp20, HpaA, and CagL) in Mongolian gerbils. Helicobacter. 22(6):12428.
   Web of Science ®Google Scholar
• Guzman J, Téné N, Touchard A, Castillo D, Belkhelfa H, Haddioui-Hbabi L, Treilhou M, Sauvain M. 2018. Anti-Helicobacter pylori properties of the ant-venom peptide bicarinalin. Toxins. 10:10.
   Web of Science ®Google Scholar
• Hamblin MR, Viveiros J, Yang C, Ahmadi A, Ganz RA, Tolkoff MJ. 2005. Helicobacter pylori accumulates photoactive porphyrins and is killed by visible light. Antimicrob Agents Chemother. 49(7):2822–2827.
   PubMed Web of Science ®Google Scholar
• He C, Peng C, Wang H, Ouyang Y, Zhu Z, Shu X, Zhu Y, Lu N. 2019. The eradication of Helicobacter pylori restores rather than disturbs the gastrointestinal microbiota in asymptomatic young adults. Helicobacter. 24(4):e12590.
   PubMed Web of Science ®Google Scholar
• Heuler J, Fortier L-C, Sun X. 2021. Clostridioides difficile phage biology and application. FEMS Microbiol Rev. DOI:https://doi.org/10.1093/femsre/fuab012.
   Google Scholar
• Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, Morelli L, Canani RB, Flint HJ, Salminen S, et al. 2014. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 11(8):506–514.
   PubMed Web of Science ®Google Scholar
• Holmgren J, Nordqvist S, Blomquist M, Jeverstam F, Lebens M, Raghavan S. 2018. Preclinical immunogenicity and protective efficacy of an oral Helicobacter pylori inactivated whole cell vaccine and multiple mutant cholera toxin: a novel and non-toxic mucosal adjuvant. Vaccine. 36(41):6223–6230.
   PubMed Web of Science ®Google Scholar
• Homan M, Orel R. 2015. Are probiotics useful in Helicobacter pylori eradication? World J Gastroenterol. 21(37):10644–10653.
   PubMed Web of Science ®Google Scholar
• Hooi JKY, Lai WY, Ng WK, Suen MMY, Underwood FE, Tanyingoh D, Malfertheiner P, Graham DY, Wong VWS, Wu JCY, et al. 2017. Global prevalence of Helicobacter pylori infection: systematic review and meta-analysis. Gastroenterology. 153(2):420–429.
   PubMed Web of Science ®Google Scholar
• Hsu P-I, Pan C-Y, Kao JY, Tsay F-W, Peng N-J, Kao S-S, Wang H-M, Tsai T-J, Wu D-C, Chen C-L, et al. 2018. Helicobacter pylori eradication with bismuth quadruple therapy leads to dysbiosis of gut microbiota with an increased relative abundance of Proteobacteria and decreased relative abundances of Bacteroidetes and Actinobacteria. Helicobacter. 23(4):e12498.
   PubMed Web of Science ®Google Scholar
• Hwang I-R, Kodama T, Kikuchi S, Sakai K, Peterson LE, Graham DY, Yamaoka Y. 2002. Effect of interleukin 1 polymorphisms on gastric mucosal interleukin 1β production in Helicobacter pylori infection. Gastroenterology. 123(6):1793–1803.
   PubMed Web of Science ®Google Scholar
• IARC. 1994. Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the evaluation of carcinogenic risks to humans Lyon, 7-14 June 1994. IARC Monogr Eval Carcinog Risks Hum. 61:1–241.
   PubMedGoogle Scholar
• Ierardi E, Losurdo G, Fortezza RF, La Principi M, Barone M, Leo AD. 2019. Optimizing proton pump inhibitors in Helicobacter pylori treatment: old and new tricks to improve effectiveness. World J Gastroenterol. 25(34):5097–5104.
   PubMed Web of Science ®Google Scholar
• Im BN, Shin H, Lim B, Lee J, Kim KS, Park JM, Na K. 2021. Helicobacter pylori-targeting multiligand photosensitizer for effective antibacterial endoscopic photodynamic therapy. Biomaterials. 271:120745.
   PubMed Web of Science ®Google Scholar
• Imani G, Mehrpoya M, Khalilian A, Dastan D, Imani B. 2020. Effects of cinnamon extract on complications of treatment and eradication of Helycobacter pylori in infected people Implication for health policy/practice/research/medical education. J Herbmed Pharmacol. 9(1):55–60.
   Google Scholar
• ImevaX. 2020. ImevaX webpage. Munich (Germany): Imevax Gmbh; [Accessed 2020 March 25]. http://www.imevax.com/overview. 146
   Google Scholar
• Ji J, Yang H. 2020. Using probiotics as supplementation for Helicobacter pylori antibiotic therapy. Int J Mol Sci. 21(3):1136.
   Web of Science ®Google Scholar
• Jiang M, Ma L, Huang Y, Wu H, Dou J, Zhou C. 2020. Antimicrobial activities of peptide Cbf-K16 against drug-resistant Helicobacter pylori infection in vitro and in vivo. Microb Pathog. 138:103847.
   PubMed Web of Science ®Google Scholar
• Jing Z-W, Luo M, Jia Y-Y, Li C, Zhou S-Y, Mei Q-B, Zhang B-L. 2018. Anti-Helicobacterpylori effectiveness and targeted delivery performance of amoxicillin-UCCs-2/TPP nanoparticles based on ureido-modified chitosan derivative. Int J Biol Macromol. 115:367–374.
   PubMed Web of Science ®Google Scholar
• Kao C-Y, Sheu B-S, Wu J-J. 2016. Helicobacter pylori infection: an overview of bacterial virulence factors and pathogenesis. Biomed J. 39(1):14–23.
   PubMed Web of Science ®Google Scholar
• Khan M, Khan S, Ali A, Akbar H, Sayaf AM, Khan A, Wei D-Q. 2019. Immunoinformatics approaches to explore Helicobacter Pylori proteome (Virulence Factors) to design B and T cell multi-epitope subunit vaccine. Sci Rep. 9(1):13321.
   PubMedGoogle Scholar
• Kharkwal GB, Sharma SK, Huang YY, Dai T, Hamblin MR. 2011. Photodynamic therapy for infections: clinical applications. Lasers Surg Med. 43(7):755–767.
   PubMed Web of Science ®Google Scholar
• Khoder G, Al-Menhali AA, Al-Yassir F, Karam SM. 2016. Potential role of probiotics in the management of gastric ulcer (Review). Exp Ther Med. 12(1):3–17.
   PubMed Web of Science ®Google Scholar
• Klymiuk I, Bilgilier C, Stadlmann A, Thannesberger J, Kastner M-T, Högenauer C, Püspök A, Biowski-Frotz S, Schrutka-Kölbl C, Thallinger GG, et al. 2017. The human gastric microbiome is predicated upon infection with Helicobacter pylori. Front Microbiol. 8:2508.
   PubMed Web of Science ®Google Scholar
• Korona-Glowniak I, Glowniak-Lipa A, Ludwiczuk A, Baj T, Malm A. 2020. The in vitro activity of essential oils against Helicobacter pylori growth and urease activity. Molecules. 25(3):25.
   Web of Science ®Google Scholar
• Kravanja G, Primožič M, Knez Ž, Leitgeb M. 2019. Chitosan-based (nano)materials for novel biomedical applications. Molecules. 24(10):24.
   Web of Science ®Google Scholar
• Krupovic M, Prangishvili D, Hendrix RW, Bamford DH. 2011. Genomics of bacterial and archaeal viruses: dynamics within the prokaryotic virosphere. Microbiol Mol Biol Rev. 75(4):610–635.
   PubMed Web of Science ®Google Scholar
• Kutateladze M, Adamia R. 2010. Bacteriophages as potential new therapeutics to replace or supplement antibiotics. Trends Biotechnol. 28(12):591–595.
   PubMed Web of Science ®Google Scholar
• Lee C-Y, Shih H-C, Yu M-C, Lee M-Y, Chang Y-L, Lai Y-Y, Lee Y-C, Kuan Y-H, Lin C-C. 2017. Evaluation of the potential inhibitory activity of a combination of L. acidophilus, L. rhamnosus and L. sporogenes on Helicobacter pylori: a randomized double-blind placebo-controlled clinical trial. Chin J Integr Med. 23(3):176–182.
   PubMed Web of Science ®Google Scholar
• Lehours P, Vale FF, Bjursell MK, Melefors O, Advani R, Glavas S, Guegueniat J, Gontier E, Lacomme S, Alves Matos A, et al. 2011. Genome sequencing reveals a phage in Helicobacter pylori. MBio. 2(6):e00239–11.
   PubMed Web of Science ®Google Scholar
• Li Z, Ren B, Tan H, Liu S, Wang W, Pang Y, Lin J, Zeng C. 2016. Capsule design for blue light therapy against Helicobacter pylori. PLoS One. 11(1):e0147531.
   PubMed Web of Science ®Google Scholar
• Liao J, Zheng Q, Liang X, Zhang W, Sun Q, Liu W, Xiao S, Graham DY, Lu H. 2013. Effect of fluoroquinolone resistance on 14-day levofloxacin triple and triple plus Bismuth quadruple therapy. Helicobacter. 18(5):373–377.
   PubMed Web of Science ®Google Scholar
• Lin YH, Lu KY, Tseng CL, Wu JY, Chen CH, Mi FL. 2017. Development of genipin-crosslinked fucoidan/chitosan-N-arginine nanogels for preventing Helicobacter infection. Nanomedicine. 12(12):1491–1510.
   PubMed Web of Science ®Google Scholar
• Liou J, Lee Y, Wu M. 2020. Treatment of Helicobacter pylori infection and its long-term impacts on gut microbiota. J Gastroenterol Hepatol. 35(7):1107–1116.
   PubMed Web of Science ®Google Scholar
• Liou J-M, Lee Y-C, El-Omar EM, Wu M-S. 2019. Efficacy and long-term safety of H. pylori eradication for gastric cancer prevention. Cancers. 11:593–593.
   Web of Science ®Google Scholar
• Liu H, Liu W, Tan Z, Zeng Z, Yang H, Luo S, Wang L, Xi T, Xing Y. 2018. Promoting immune efficacy of the oral Helicobacter pylori vaccine by HP55/PBCA nanoparticles against the gastrointestinal environment. Mol Pharm. 15(8):3177–3186.
   PubMedGoogle Scholar
• Liu M, Zhong Y, Chen J, Liu Y, Tang C, Wang X, Zhang Y, Wang P, Logan SM, Chen W, et al. 2020. Oral immunization of mice with a multivalent therapeutic subunit vaccine protects against Helicobacter pylori infection. Vaccine. 38(14):3031–3041.
   PubMed Web of Science ®Google Scholar
• Liu Q, Meng X, Li Y, Zhao C-N, Tang G-Y, Li S, Gan R-Y, Li H-B. 2018. Natural products for the prevention and management of Helicobacter pylori infection. Compr Rev Food Sci Food Saf. 17(4):937–952.
   PubMed Web of Science ®Google Scholar
• Liu WZ, Xie Y, Lu H, Cheng H, Zeng ZR, Zhou LY, Chen Y, Wang JB, Du YQ, Lu NH. 2018. Fifth Chinese National Consensus report on the management of Helicobacter pylori infection. Helicobacter. 23(2):e12475.
   PubMed Web of Science ®Google Scholar
• Loc-Carrillo C, Abedon ST. 2011. Pros and cons of phage therapy. Bacteriophage. 1(2):111–114.
   PubMedGoogle Scholar
• Lood R, Winer BY, Pelzek AJ, Diez-Martinez R, Thandar M, Euler CW, Schuch R, Fischetti VA. 2015. Novel phage lysin capable of killing the multidrug-resistant gram-negative bacterium Acinetobacter baumannii in a mouse bacteremia model. Antimicrob Agents Chemother. 59(4):1983–1991.
   PubMed Web of Science ®Google Scholar
• Lopes D, Nunes C, Martins MCL, Sarmento B, Reis S. 2014. Eradication of Helicobacter pylori: past, present and future. J Control Release. 189:169–186.
   PubMed Web of Science ®Google Scholar
• Losurdo G, Cubisino R, Barone M, Principi M, Leandro G, Ierardi E, Leo AD. 2018. Probiotic monotherapy and Helicobacter pylori eradication: a systematic review with pooled-data analysis. WJG. 24(1):139–149.
   PubMed Web of Science ®Google Scholar
• Lu C, Sang J, He H, Wan X, Lin Y, Li L, Li Y, Yu C. 2016. Probiotic supplementation does not improve eradication rate of Helicobacter pylori infection compared to placebo based on standard therapy: a meta-analysis. Sci Rep. 6:1–10.
   PubMed Web of Science ®Google Scholar
• Lu W, Wise MJ, Tay CY, Windsor HM, Marshall BJ, Peacock C, Perkins T. 2014. Comparative analysis of the full genome of Helicobacter pylori isolate Sahul64 identifies genes of high divergence. J Bacteriol. 196(5):1073–1083.
   PubMed Web of Science ®Google Scholar
• Lukacik P, Barnard TJ, Keller PW, Chaturvedi KS, Seddiki N, Fairman JW, Noinaj N, Kirby TL, Henderson JP, Steven AC, et al. 2012. Structural engineering of a phage lysin that targets Gram-negative pathogens. Proc Natl Acad Sci USA. 109(25):9857–9862.
   PubMed Web of Science ®Google Scholar
• Luo C-H, Chiou P-Y, Yang C-Y, Lin N-T. 2012. Genome, integration, and transduction of a novel temperate phage of Helicobacter pylori. J Virol. 86(16):8781–8792.
   PubMed Web of Science ®Google Scholar
• Luo M, Jia Y-Y, Jing Z-W, Li C, Zhou S-Y, Mei Q-B, Zhang B-L. 2018. Construction and optimization of pH-sensitive nanoparticle delivery system containing PLGA and UCCs-2 for targeted treatment of Helicobacter pylori. Colloids Surf B Biointerfaces. 164:11–19.
   PubMed Web of Science ®Google Scholar
• Ma J, Hiratsuka T, Etoh T, Akada J, Fujishima H, Shiraishi N, Yamaoka Y, Inomata M. 2018. Anti-proliferation effect of blue light-emitting diodes against antibiotic-resistant Helicobacter pylori. J Gastroenterol Hepatol. 33(8):1492–1499.
   PubMed Web of Science ®Google Scholar
• Ma J, Qiu J, Wang S, Ji Q, Xu D, Wang H, Wu Z, Liu Q. 2021. A novel design of multi-epitope vaccine against Helicobacter pylori by immunoinformatics approach. Int J Pept Res Ther. 27:1027–1042.
   PubMed Web of Science ®Google Scholar
• Mahlapuu M, Håkansson J, Ringstad L, Björn C. 2016. Antimicrobial peptides: an emerging category of therapeutic agents. Front Cell Infect Microbiol. 6:194.
   PubMed Web of Science ®Google Scholar
• Malfertheiner P, Megraud F, O’Morain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuipers EJ. 2007. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut. 56(6):772–781.
   PubMed Web of Science ®Google Scholar
• Malfertheiner P, Megraud F, O’Morain CA, Gisbert JP, Kuipers EJ, Axon AT, Bazzoli F, Gasbarrini A, Atherton J, Graham DY, et al. 2017. Management of Helicobacter pylori infection-the Maastricht V/florence consensus report. Gut. 66(1):6–30.
   PubMed Web of Science ®Google Scholar
• Malfertheiner P, Schultze V, Rosenkranz B, Kaufmann SHE, Ulrichs T, Novicki D, Norelli F, Contorni M, Peppoloni S, Berti D, et al. 2008. Safety and Immunogenicity of an Intramuscular Helicobacter pylori vaccine in noninfected volunteers: a phase I study. Gastroenterology. 135(3):787–795.
   PubMed Web of Science ®Google Scholar
• Malfertheiner P, Selgrad M, Wex T, Romi B, Borgogni E, Spensieri F, Zedda L, Ruggiero P, Pancotto L, Censini S, et al. 2018. Efficacy, immunogenicity, and safety of a parenteral vaccine against Helicobacter pylori in healthy volunteers challenged with a Cag-positive strain: a randomised, placebo-controlled phase 1/2 study. Lancet Gastroenterol Hepatol. 3(10):698–707.
   PubMed Web of Science ®Google Scholar
• Marone P, Bono L, Leone E, Bona S, Carretto E, Perversi L. 2001. Bactericidal activity of Pistacia lentiscus mastic gum against Helicobacter pylori. J Chemother. 13(6):611–614.
   PubMed Web of Science ®Google Scholar
• Marrero Rolon R, Cunningham SA, Mandrekar JN, Polo ET, Patel R. 2021. Clinical evaluation of a real-time PCR assay for simultaneous detection of Helicobacter pylori and genotypic markers of clarithromycin resistance directly from stool. J Clin Microbiol. 59(5):e03040.
   PubMed Web of Science ®Google Scholar
• Marshall B, Armstrong J, Francis G, Nokes N, Wee S. 1987. Antibacterial action of bismuth in relation to Campylobacter pyloridis colonization and gastritis. Digestion. 37:16–30.
   PubMed Web of Science ®Google Scholar
• Masuda S, Masuda H, Shimamura Y, Sugiyama C, Takabayashi F. 2017. Improvement effects of Wasabi (Wasabi japonica) leaves and allyl isothiocyanate on stomach lesions of Mongolian gerbils infected with Helicobacter pylori. Nat Prod Commun. 12:595–598.
   PubMed Web of Science ®Google Scholar
• McFarland LV, Huang Y, Wang L, Malfertheiner P. 2016. Systematic review and meta-analysis: multi-strain probiotics as adjunct therapy for Helicobacter pylori eradication and prevention of adverse events. United European Gastroenterol J. 4(4):546–561.
   PubMed Web of Science ®Google Scholar
• Megraud F, Bruyndonckx R, Coenen S, Wittkop L, Huang T-D, Hoebeke M, Bénéjat L, Lehours P, Goossens H, Glupczynski Y. 2021. Helicobacter pylori resistance to antibiotics in Europe in 2018 and its relationship to antibiotic consumption in the community. Gut. 2021:324032.
   Google Scholar
• Mejías-Luque R, Gerhard M. 2017. Immune evasion strategies and persistence of Helicobacter pylori. Curr Top Microbiol Immunol. 400:53–71.
   PubMed Web of Science ®Google Scholar
• Melo LDR, Oliveira H, Pires DP, Dabrowska K, Azeredo J. 2020. Phage therapy efficacy: a review of the last 10 years of preclinical studies. Crit Rev Microbiol. 46(1):78–99.
   PubMed Web of Science ®Google Scholar
• Miyamoto T, Okimoto T, Kuwano M. 2014. Chemical composition of the essential oil of mastic gum and their antibacterial activity against drug-resistant Helicobacter pylori. Nat Prod Bioprospect. 4(4):227–231.
   PubMedGoogle Scholar
• Molina-Infante J, Gisbert JP. 2014. Optimizing clarithromycin-containing therapy for Helicobacter pylori in the era of antibiotic resistance. World J Gastroenterol. 20(30):10338–10347.
   PubMed Web of Science ®Google Scholar
• Monteiro R, Pires DP, Costa AR, Azeredo J. 2019. Phage therapy: going temperate? Trends Microbiol. 27(4):368–378.
   PubMed Web of Science ®Google Scholar
• Muñoz AB, Trespalacios ‐Rangel AA, Vale FF. 2021. An American lineage of Helicobacter pylori prophages found in Colombia. Helicobacter. 26(2):e12779.
   PubMed Web of Science ®Google Scholar
• Murakami K, Sakurai Y, Shiino M, Funao N, Nishimura A, Asaka M. 2016. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Gut. 65(9):1439–1446.
   PubMed Web of Science ®Google Scholar
• Namkin K, Zardast M, Basirinejad F. 2016. Saccharomyces boulardii in Helicobacter pylori eradication in children: a randomized trial from Iran. Iran J Pediatr. 26(1):e3768.
   PubMed Web of Science ®Google Scholar
• Narayana JL, Huang H-N, Wu C-J, Chen J-Y. 2015. Efficacy of the antimicrobial peptide TP4 against Helicobacter pylori infection: in vitro membrane perturbation via micellization and in vivo suppression of host immune responses in a mouse model. Oncotarget. 6(15):12936–12954.
   PubMedGoogle Scholar
• Natan M, Banin E. 2017. From nano to micro: using nanotechnology to combat microorganisms and their multidrug resistance. FEMS Microbiol Rev. 41(3):302–322.
   PubMed Web of Science ®Google Scholar
• Neshani A, Zare H, Akbari Eidgahi MR, Hooshyar Chichaklu A, Movaqar A, Ghazvini K. 2019. Review of antimicrobial peptides with anti-Helicobacter pylori activity. Helicobacter. 24(1):e12555.
   PubMed Web of Science ®Google Scholar
• Nishizawa T, Maekawa T, Watanabe N, Harada N, Hosoda Y, Yoshinaga M, Yoshio T, Ohta H, Inoue S, Toyokawa T, et al. 2015. Clarithromycin versus metronidazole as first-line Helicobacter pylori eradication: a multicenter, prospective, randomized controlled study in Japan. J Clin Gastroenterol. 49(6):468–471.
   PubMed Web of Science ®Google Scholar
• Nishizawa T, Suzuki H. 2014. Mechanisms of Helicobacter pylori antibiotic resistance and molecular testing. Front Mol Biosci. 1:19.
   PubMed Web of Science ®Google Scholar
• Nuding S, Gersemann M, Hosaka Y, Konietzny S, Schaefer C, Beisner J, Schroeder BO, Ostaff MJ, Saigenji K, Ott G, et al. 2013. Gastric antimicrobial peptides fail to eradicate Helicobacter pylori infection due to selective induction and resistance. PLoS One. 8(9):e73867.
   PubMed Web of Science ®Google Scholar
• O’Connor A, Furuta T, Gisbert JP, O’Morain C. 2020. Review - treatment of Helicobacter pylori infection 2020. Helicobacter. 25:e12743.
   PubMed Web of Science ®Google Scholar
• O’Connor JPA, Taneike I, O’Morain C. 2009. Improving compliance with Helicobacter pylori eradication therapy: when and how? Therap Adv Gastroenterol. 2(5):273–279.
   PubMedGoogle Scholar
• Oh B, Kim B-S, Kim JW, Kim JS, Koh S-J, Kim BG, Lee KL, Chun J. 2016. The effect of probiotics on gut microbiota during the Helicobacter pylori eradication: randomized controlled trial. Helicobacter. 21(3):165–174.
   PubMed Web of Science ®Google Scholar
• Okińczyc P, Paluch E, Franiczek R, Widelski J, Wojtanowski KK, Mroczek T, Krzyżanowska B, Skalicka-Woźniak K, Sroka Z. 2020. Antimicrobial activity of Apis mellifera L. and Trigona sp. propolis from Nepal and its phytochemical analysis. Biomed Pharmacother. 129:110435.
   PubMed Web of Science ®Google Scholar
• Oliveira AV, Ferreira AL, Nunes S, Dandlen SA, Miguel MDG, Faleiro ML. 2017. Antibacterial activity of propolis extracts from the south of Portugal. Pak J Pharm Sci. 30:1–9.
   PubMed Web of Science ®Google Scholar
• Oliveira H, Azeredo J, Lavigne R, Kluskens LD. 2012. Bacteriophage endolysins as a response to emerging foodborne pathogens. Trends Food Sci Technol. 28(2):103–115.
   Web of Science ®Google Scholar
• Oliveira H, Thiagarajan V, Walmagh M, Sillankorva S, Lavigne R, Neves-Petersen MT, Kluskens LD, Azeredo J. 2014. A thermostable Salmonella phage endolysin, Lys68, with broad bactericidal properties against gram-negative pathogens in presence of weak acids. PLoS One. 9(10):e108376.
   PubMed Web of Science ®Google Scholar
• Oliveira H, Vilas Boas D, Mesnage S, Kluskens LD, Lavigne R, Sillankorva S, Secundo F, Azeredo J. 2016. Structural and enzymatic characterization of ABgp46, a novel phage endolysin with broad anti-gram-negative bacterial activity. Front Microbiol. 7:208.
   PubMed Web of Science ®Google Scholar
• O’Morain NR, Dore MP, O’Connor AJP, Gisbert JP, O’Morain CA. 2018. Treatment of Helicobacter pylori infection in 2018. Helicobacter. 23:e12519.
   PubMedGoogle Scholar
• Pan X, Ke H, Niu X, Li S, Lv J, Pan L. 2018. Protection against Helicobacter pylori infection in BALB/c mouse model by oral administration of multivalent epitope-based vaccine of cholera toxin B subunit-HUUC. Front Immunol. 9:1003.
   PubMed Web of Science ®Google Scholar
• Paraschos S, Mitakou S, Skaltsounis A-L. 2012. Chios gum mastic: a review of its biological activities. Curr Med Chem. 19(14):2292–2302.
   PubMed Web of Science ®Google Scholar
• Parsons BN, Ijaz UZ, D’Amore R, Burkitt MD, Eccles R, Lenzi L, Duckworth CA, Moore AR, Tiszlavicz L, Varro A, et al. 2017. Comparison of the human gastric microbiota in hypochlorhydric states arising as a result of Helicobacter pylori-induced atrophic gastritis, autoimmune atrophic gastritis and proton pump inhibitor use. PLoS Pathog. 13(11):e1006653.
   PubMed Web of Science ®Google Scholar
• Pasala C, Chilamakuri CSR, Katari SK, Nalamolu RM, Bitla AR, Amineni U. 2019. Epitope-driven common subunit vaccine design against H. pylori strains. J Biomol Struct Dyn. 37(14):3740–3750.
   PubMed Web of Science ®Google Scholar
• Pasala C, Chilamakuri CSR, Katari SK, Nalamolu RM, Bitla AR, Umamaheswari A. 2018. An in silico study: novel targets for potential drug and vaccine design against drug resistant H. pylori. Microb Pathog. 122:156–161.
   PubMed Web of Science ®Google Scholar
• Pelgrift RY, Friedman AJ. 2013. Nanotechnology as a therapeutic tool to combat microbial resistance. Adv Drug Deliv Rev. 65(13–14):1803–1815.
   PubMed Web of Science ®Google Scholar
• Pero R, Brancaccio M, Laneri S, Biasi MG, De Lombardo B, Scudiero O. 2019. A novel view of human Helicobacter pylori infections: interplay between microbiota and beta-defensins. Biomolecules. 9(6):237.
   Web of Science ®Google Scholar
• Pero R, Coretti L, Nigro E, Lembo F, Laneri S, Lombardo B, Daniele A, Scudiero O. 2017. β-defensins in the fight against Helicobacter pylori. Molecules. 22:1–17.
   Web of Science ®Google Scholar
• Ping Y, Hu X, Yao Q, Hu Q, Amini S, Miserez A, Tang G. 2016. Engineering bioinspired bacteria-adhesive clay nanoparticles with a membrane-disruptive property for the treatment of Helicobacter pylori infection. Nanoscale. 8(36):16486–16498.
   PubMed Web of Science ®Google Scholar
• Pirnay J-P, De Vos D, Verbeken G, Merabishvili M, Chanishvili N, Vaneechoutte M, Zizi M, Laire G, Lavigne R, Huys I, et al. 2011. The phage therapy paradigm: prêt-à-porter or sur-mesure? Pharm Res. 28(4):934–937.
   PubMed Web of Science ®Google Scholar
• Ram MR, Teh X, Rajakumar T, Goh KL, Leow AHR, Poh BH, Mariappan V, Shankar EM, Loke MF, Vadivelu J. 2019. Polymorphisms in the host CYP2C19 gene and antibiotic-resistance attributes of Helicobacter pylori isolates influence the outcome of triple therapy. J Antimicrob Chemother. 74(1):11–16.
   PubMed Web of Science ®Google Scholar
• Ramesh P, Saravanan K, Manogar P, Johnson J, Vinoth E, Mayakannan M. 2021. Green synthesis and characterization of biocompatible zinc oxide nanoparticles and evaluation of its antibacterial potential. Sens Bio-Sensing Res. 31:100995.
   Google Scholar
• Rhoads DD, Wolcott RD, Kuskowski MA, Wolcott BM, Ward LS, Sulakvelidze A. 2009. Bacteriophage therapy of venous leg ulcers in humans: results of a phase I safety trial. J Wound Care. 18(6):237–243.
   PubMedGoogle Scholar
• Romano G, Tortora G, Calusi S, Orsini B, Gnerucci A, Fusi F. 2016. Minimally invasive ingestible device to perform anti-bacterial phototherapy in the stomach. Phys Medica. 32:215.
   Google Scholar
• Sabouri Ghannad M, Mohammadi A. 2012. Time to re-evaluate the potential of phage therapy as a promising agent to control multidrug-resistant bacteria. Iran J Basic Med Sci. 15(2):693–701.
   PubMed Web of Science ®Google Scholar
• Sahin H. 2016. Honey as an apitherapic product: its inhibitory effect on urease and xanthine oxidase. J Enzyme Inhib Med Chem. 31(3):490–494.
   PubMed Web of Science ®Google Scholar
• Sakarya S, Gunay N. 2014. Saccharomyces boulardii expresses neuraminidase activity selective for α2,3-linked sialic acid that decreases Helicobacter pylori adhesion to host cells. APMIS. 122(10):941–950.
   PubMed Web of Science ®Google Scholar
• Salmond GPC, Fineran PC. 2015. A century of the phage: past, present and future. Nat Rev Microbiol. 13(12):777–786.
   PubMed Web of Science ®Google Scholar
• Santos AM, Lopes T, Oleastro M, Gato IV, Floch P, Benejat L, Chaves P, Pereira T, Seixas E, Machado J, et al. 2015. Curcumin inhibits gastric inflammation induced by Helicobacter pylori infection in a mouse model. Nutrients. 7(1):306–320.
   PubMed Web of Science ®Google Scholar
• Santos AM, Lopes T, Oleastro M, Pereira T, Alves CC, Seixas E, Chaves P, Machado J, Guerreiro AS. 2018. Cyclooxygenase inhibition with curcumin in Helicobacter pylori infection. Nutrire. 43:7. DOI:https://doi.org/10.1186/s41110-018-0070-5.
   Google Scholar
• Santos RS, Figueiredo C, Azevedo NF, Braeckmans K, De Smedt SC. 2018. Nanomaterials and molecular transporters to overcome the bacterial envelope barrier: towards advanced delivery of antibiotics. Adv Drug Deliv Rev. 136–137:28–48.
   PubMed Web of Science ®Google Scholar
• Saracino IM, Pavoni M, Zullo A, Fiorini G, Lazzarotto T, Borghi C, Vaira D. 2021. Next generation sequencing for the prediction of the antibiotic resistance in Helicobacter pylori: a literature review. Antibiotics. 10(4):437.
   Google Scholar
• Saravanakumar K, Chellia R, Hu X, Kathiresan K, Oh DH, Wang MH. 2019. Eradication of Helicobacter pylori through the inhibition of urease and peptide deformylase: computational and biological studies. Microb Pathog. 128:236–244.
   PubMed Web of Science ®Google Scholar
• Saravanan M, Gopinath V, Chaurasia MK, Syed A, Ameen F, Purushothaman N. 2018. Green synthesis of anisotropic zinc oxide nanoparticles with antibacterial and cytofriendly properties. Microb Pathog. 115:57–63.
   PubMed Web of Science ®Google Scholar
• Savoldi A, Carrara E, Graham DY, Conti M, Tacconelli E. 2018. Prevalence of antibiotic resistance in Helicobacter pylori: a systematic review and meta-analysis in World Health Organization regions materials and methods search strategy and selection criteria data extraction. Gastroenterology. 155(5):1372–1382.
   PubMed Web of Science ®Google Scholar
• Schmid EN, Von Recklinghausen G, Ansorg R. 1990. Bacteriophages in Helicobacter (Campylobacter) pylori. J Med Microbiol. 32(2):101–104.
   PubMed Web of Science ®Google Scholar
• Secka O, Vale FF, Buissonnière A, Thomas JE, Mégraud F, Lehours P. 2017. Phylogeographic agreement between prophage and bacterial housekeeping genes in Helicobacter pylori strains from The Gambia. Helicobacter. 22:e12394.
   Web of Science ®Google Scholar
• Sgouras D, Maragkoudakis P, Petraki K, Martinez-Gonzalez B, Eriotou E, Michopoulos S, Kalantzopoulos G, Tsakalidou E, Mentis A. 2004. In Vitro and In Vivo Inhibition of Helicobacter pylori by Lactobacillus casei Strain Shirota. Appl Environ Microbiol. 70(1):518–526.
   PubMed Web of Science ®Google Scholar
• Shafaghi A, Pourkazemi A, Khosravani M, Fakhrie Asl S, Amir Maafi A, Atrkar Roshan Z, Abaspour Rahimabad J. 2016. The effect of probiotic plus prebiotic supplementation on the tolerance and efficacy of Helicobacter pylori eradication quadruple therapy: a randomized prospective double blind controlled trial. Middle East J Dig Dis. 8(3):179–188.
   PubMedGoogle Scholar
• Sharifi MS, Hazell SL. 2011. Isolation, analysis and antimicrobial activity of the acidic fractions of Mastic, Kurdica, Mutica and Cabolica gums from genus Pistacia. Glob J Health Sci. 4(1):217–228.
   PubMedGoogle Scholar
• Song H, Zhou L, Liu D, Ge L, Li Y. 2019. Probiotic effect on Helicobacter pylori attachment and inhibition of inflammation in human gastric epithelial cells. Exp Ther Med. 18(3):1551–1562.
   PubMed Web of Science ®Google Scholar
• Song H-Y, Zhou L, Li Y, Liu D, Yao X-J. 2018. What roles do probiotics play in the eradication of Helicobacter pylori? Current knowledge and ongoing research. Gastroenterol Res Pract. 2018:9379480–9379489. eCollection 2018.
   PubMed Web of Science ®Google Scholar
• Song Z, Li B, Zhang Y, Li R, Ruan H, Wu J, Liu Q. 2020. Outer membrane vesicles of Helicobacter pylori 7.13 as adjuvants promote protective efficacy against Helicobacter pylori infection. Front Microbiol. 11:1340.
   PubMed Web of Science ®Google Scholar
• Stubljar D, Jukic T, Ihan A. 2018. How far are we from vaccination against Helicobacter pylori infection? Expert Rev Vaccines. 17(10):935–945.
   PubMed Web of Science ®Google Scholar
• Sugimoto M, Hira D, Murata M, Kawai T, Terada T. 2020. Effect of antibiotic susceptibility and cyp3a4/5 and cyp2c19 genotype on the outcome of vonoprazan-containing Helicobacter pylori eradication therapy. Antibiotics. 9:1–11.
   Google Scholar
• Sutton P, Boag JM. 2019. Status of vaccine research and development for Helicobacter pylori. Vaccine. 37(50):7295–7299.
   PubMed Web of Science ®Google Scholar
• Suzuki S, Esaki M, Kusano M, Ikehara H, Gotoda T. 2019. Development of Helicobacter pylori treatment: how do we manage antimicrobial resistance? World J Gastroenterol. 25(16):1907–1912.
   PubMed Web of Science ®Google Scholar
• Suzuki S, Gotoda T, Kusano C, Ikehara H, Ichijima R, Ohyauchi M, Ito H, Kawamura M, Ogata Y, Ohtaka M, et al. 2020. Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan. Gut. 69(6):1019–1026.
   PubMed Web of Science ®Google Scholar
• Svennerholm A-M, Lundgren A. 2007. Progress in vaccine development against Helicobacter pylori. FEMS Immunol Med Microbiol. 50(2):146–156.
   PubMedGoogle Scholar
• Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, Pulcini C, Kahlmeter G, Kluytmans J, Carmeli Y, et al. 2018. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 18(3):318–327.
   PubMed Web of Science ®Google Scholar
• Tan Z, Liu W, Liu H, Li C, Zhang Y, Meng X, Tang T, Xi T, Xing Y. 2017. Oral Helicobacter pylori vaccine-encapsulated acid-resistant HP55/PLGA nanoparticles promote immune protection. Eur J Pharm Biopharm. 111:33–43.
   PubMed Web of Science ®Google Scholar
• Thiberge J-M, Boursaux-Eude C, Lehours P, Dillies M-A, Creno S, Coppée J-Y, Rouy Z, Lajus A, Ma L, Burucoa C, et al. 2010. From array-based hybridization of Helicobacter pylori isolates to the complete genome sequence of an isolate associated with MALT lymphoma. BMC Genomics. 11:368.
   PubMed Web of Science ®Google Scholar
• Thung I, Aramin H, Vavinskaya V, Gupta S, Park JY, Crowe SE, Valasek MA. 2016. Review article: the global emergence of Helicobacter pylori antibiotic resistance. Aliment Pharmacol Ther. 43(4):514–533.
   PubMed Web of Science ®Google Scholar
• Tortora G, Orsini B, Pecile P, Menciassi A, Fusi F, Romano G. 2016. An ingestible capsule for the photodynamic therapy of Helicobacter pylori infection. IEEE/ASME Trans Mechatron. 21(4):1935–1942.
   Web of Science ®Google Scholar
• Tshibangu-Kabamba E, Yamaoka Y. 2021. Helicobacter pylori infection and antibiotic resistance - from biology to clinical implications. Nat Rev Gastroenterol Hepatol. 18(9):613–617.
   PubMed Web of Science ®Google Scholar
• Twort FW. 1915. An investigation on the nature of ultra-microscopic viruses. Lancet. 186(4814):1241–1243.
   Google Scholar
• Uchiyama J, Takemura-Uchiyama I, Kato S-I, Takeuchi H, Sakaguchi Y, Ujihara T, Daibata M, Shimakura H, Okamoto N, Sakaguchi M, et al. 2016. Screening of KHP30-like prophages among Japanese Helicobacter pylori strains, and genetic analysis of a defective KHP30-like prophage sequence integrated in the genome of the H. pylori strain NY40. FEMS Microbiol Lett. 363(16):fnw157.
   PubMed Web of Science ®Google Scholar
• Uchiyama J, Takeuchi H, Kato S-i, Gamoh K, Takemura-Uchiyama I, Ujihara T, Daibata M, Matsuzaki S. 2013. Characterization of Helicobacter pylori bacteriophage KHP30. Appl Environ Microbiol. 79(10):3176–3184.
   PubMed Web of Science ®Google Scholar
• Uchiyama J, Takeuchi H, Kato S-i, Takemura-Uchiyama I, Ujihara T, Daibata M, Matsuzaki S. 2012. Complete genome sequences of two Helicobacter pylori bacteriophages isolated from Japanese patients. J Virol. 86(20):11400–11401.
   PubMed Web of Science ®Google Scholar
• Urrutia-Baca VH, Escamilla-García E, de la Garza-Ramos MA, Tamez-Guerra P, Gomez-Flores R, Urbina-Ríos CS. 2018. In vitro antimicrobial activity and downregulation of virulence gene expression on Helicobacter pylori by reuterin. Probiotics & Antimicro Prot. 10(2):168–175.
   PubMed Web of Science ®Google Scholar
• Vale FF, Matos APA, Carvalho P, Vítor JMB. 2008. Helicobacter pylori phage screening. Microsc Microanal. 14(S3):150–151.
   PubMedGoogle Scholar
• Vale FF, Nunes A, Oleastro M, Gomes JP, Sampaio DA, Rocha R, Vítor JMB, Engstrand L, Pascoe B, Berthenet E, et al. 2017. Genomic structure and insertion sites of Helicobacter pylori prophages from various geographical origins. Sci Rep. 7:42471.
   PubMed Web of Science ®Google Scholar
• Vale FF, Oleastro M. 2014. Overview of the phytomedicine approaches against Helicobacter pylori. World J Gastroenterol. 20(19):5594–5609.
   PubMed Web of Science ®Google Scholar
• Vale FF, Vadivelu J, Oleastro M, Breurec S, Engstrand L, Perets TT, Mégraud F, Lehours P. 2015. Dormant phages of Helicobacter pylori reveal distinct populations in Europe. Sci Rep. 5:14333.
   PubMed Web of Science ®Google Scholar
• Van Giau V, An SSA, Hulme J. 2019. Recent advances in the treatment of pathogenic infections using antibiotics and nano-drug delivery vehicles. Drug Des Devel Ther. 13:327–343.
   PubMed Web of Science ®Google Scholar
• Viertel TM, Ritter K, Horz HP. 2014. Viruses versus bacteria-novel approaches to phage therapy as a tool against multidrug-resistant pathogens. J Antimicrob Chemother. 69(9):2326–2336.
   PubMed Web of Science ®Google Scholar
• Walmagh M, Briers Y, dos SS, Azeredo J, Lavigne R. 2012. Characterization of modular bacteriophage endolysins from myoviridae phages OBP, 201φ2-1 and PVP-SE1. PLoS One. 7(5):e36991.
   PubMed Web of Science ®Google Scholar
• Wang B, Yao M, Lv L, Ling Z, Li L. 2017. The human microbiota in health and disease. Engineering. 3(1):71–82.
   Web of Science ®Google Scholar
• Ways TMM, Lau WM, Khutoryanskiy VV. 2018. Chitosan and its derivatives for application in mucoadhesive drug delivery systems. Polymers. 10(3):10.
   Web of Science ®Google Scholar
• Wilkins T, Sequoia J, Jennings W, Dorn B. 2017. Probiotics for gastrointestinal conditions: a summary of the evidence. Am Fam Physician. 96(3):170–178.
   PubMed Web of Science ®Google Scholar
• Xu D, Zhao S, Dou J, Xu X, Zhi Y, Wen L. 2021. Engineered endolysin-based “artilysins” for controlling the gram-negative pathogen Helicobacter pylori. AMB Express. 11(1):63.
   PubMed Web of Science ®Google Scholar
• Xu L, Shao C, Li G, Shan A, Chou S, Wang J, Ma Q, Dong N. 2020. Conversion of broad-spectrum antimicrobial peptides into species-specific antimicrobials capable of precisely targeting pathogenic bacteria. Sci Rep. 10(1):944.
   PubMed Web of Science ®Google Scholar
• Yahara K, Lehours P, Vale FF. 2019. Analysis of genetic recombination and the pan-genome of a highly recombinogenic bacteriophage species. Microb Genom. 5(8):e000282.
   Web of Science ®Google Scholar
• Yang SJ, Huang CH, Yang JC, Wang CH, Shieh MJ. 2020. Residence time-extended nanoparticles by magnetic field improve the eradication efficiency of Helicobacter pylori. ACS Appl Mater Interfaces. 12(49):54316–54327.
   PubMed Web of Science ®Google Scholar
• You Y, He L, Zhang M, Zhang J. 2015. Comparative genomics of a Helicobacter pylori isolate from a Chinese Yunnan Naxi Ethnic Aborigine suggests high genetic divergence and phage insertion. PLoS One. 10(3):e0120659.
   PubMed Web of Science ®Google Scholar
• Yu M, Zhang R, Ni P, Chen S, Duan G. 2019. Efficacy of Lactobacillus-supplemented triple therapy for H. pylori eradication: a meta-analysis of randomized controlled trials. PLoS One. 14(10):e0223309.
   PubMed Web of Science ®Google Scholar
• Zeng M, Mao X-H, Li J-X, Tong W-D, Wang B, Zhang Y-J, Guo G, Zhao Z-J, Li L, Wu D-L, et al. 2015. Efficacy, safety, and immunogenicity of an oral recombinant Helicobacter pylori vaccine in children in China: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 386(10002):1457–1464.
   PubMed Web of Science ®Google Scholar
• Zhang R, Duan G, Shi Q, Chen S, Fan Q, Sun N, Xi Y. 2016. Construction of a recombinant Lactococcus lactis strain expressing a fusion protein of Omp22 and HpaA from Helicobacter pylori for oral vaccine development. Biotechnol Lett. 38(11):1911–1916.
   PubMed Web of Science ®Google Scholar
• Zhang W, Chen Q, Liang X, Liu W, Xiao S, Graham DY, Lu H. 2015. Bismuth, lansoprazole, amoxicillin and metronidazole or clarithromycin as first-line Helicobacter pylori therapy. Gut. 64(11):1715–1720.
   PubMed Web of Science ®Google Scholar
• Zhang X, Jiang A, Qi B, Yu H, Xiong Y, Zhou G, Qin M, Dou J, Wang J. 2018. Secretion expression of human neutrophil peptide 1 (HNP1) in Pichia pastoris and its functional analysis against antibiotic-resistant Helicobacter pylori. Appl Microbiol Biotechnol. 102(11):4817–4827.
   PubMed Web of Science ®Google Scholar
• Zhang X, Jiang A, Wang G, Yu H, Qi B, Xiong Y, Zhou G, Qin M, Dou J, Wang J. 2017. Fusion expression of the PGLa-AM1 with native structure and evaluation of its anti-Helicobacter pylori activity. Appl Microbiol Biotechnol. 101(14):5667–5675.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Chen Y, Lo C, Zhuang J, Angsantikul P, Zhang Q, Wei X, Zhou Z, Obonyo M, Fang RH, et al. 2019. Inhibition of pathogen adhesion by bacterial outer membrane-coated nanoparticles. Angew Chem Int Ed Engl. 58(33):11404–11408.
   PubMed Web of Science ®Google Scholar
• Zhi X, Liu Y, Lin L, Yang M, Zhang L, Zhang L, Liu Y, Alfranca G, Ma L, Zhang Q, et al. 2019. Oral pH sensitive GNS@ab nanoprobes for targeted therapy of Helicobacter pylori without disturbance gut microbiome. Nanomedicine. 20:102019.
   PubMed Web of Science ®Google Scholar
• Zhong Y, Chen J, Liu Y, Zhang Y, Tang C, Wang X, Wang P, Chen W, Wei B, Liu M. 2020. Oral immunization of BALB/c mice with recombinant Helicobacter pylori antigens and double mutant heat-labile toxin (dmLT) induces prophylactic protective immunity against H. pylori infection. Microb Pathog. 145:104229.
   PubMed Web of Science ®Google Scholar
• Zhou Z, Dong H, Huang Y, Yao S, Liang B, Xie Y, Long Y, Mai J, Gong S. 2017. Recombinant Bacillus subtilis spores expressing cholera toxin B subunit and Helicobacter pylori urease B confer protection against H. pylori in mice. J Med Microbiol. 66(1):83–89.
   PubMed Web of Science ®Google Scholar
• Zhu R, Chen K, Zheng Y-Y, Zhang H-W, Wang J-S, Xia Y-J, Dai W-Q, Wang F, Shen M, Cheng P, et al. 2014. Meta-analysis of the efficacy of probiotics in Helicobacter pylori eradication therapy. World J Gastroenterol. 20(47):18013–18021.
   PubMed Web of Science ®Google Scholar